First Patient Dosed in the Phase 1/2 Study of BEAM-301 in Glycogen Storage Disease Type Ia, Beam’s Second Clinical Stage In ...

In June, the Centers for Medicare & Medicaid Services (CMS) will name the participating states for the agency’s new Cell and ...

In chronic lymphocytic leukemia (CLL), certain recurrent genetic alterations are known to influence disease progression and ...

With AI, Google DeepMind’s AlphaFold has been able to unfold the difficult mystery around the protein-folding problem that ...

Enrollment complete in the 12 mg dose cohort (n=16) of the Phase 1b PIONEER trial of pociredir in sickle cell disease (SCD); initiated the 20 mg dose cohort ― ― On track to provide clinical data from ...

The "Sickle Cell Disease Drugs Market - A Global and Regional Analysis: Focus on Route of Administration, Distribution Channel, and Country-Level Analysis - Analysis and Forecast, 2025-2035" report ...

More perceived social support from classmates was tied to less disease severity in children with sickle cell anemia in ...

Martin Mwita, 20, is the first patient in St. Louis and among the first across the country to receive a new gene therapy for ...

Among these, 513 populations showed genetic changes or mutations in gyrA -- a gene associated with fluoroquinolone resistance ...

CHARLESTON, S.C. - Health Secretary Robert F. Kennedy Jr. used a morning keynote address before a group of state lawmakers in ...

Crispr Therapeutics is an emerging gene editing company focused on the development of Crispr/Cas9-based therapeutics. The company's proprietary platform specializes in clustered regularly interspaced ...

More than 70 percent of Japanese renal cell carcinoma patients have a specific genetic mutation pattern that is rarely found in other countries, an international team of researchers said.